You can buy or sell ABUS and other stocks, options, ETFs, and crypto commission-free!
Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded on October 6, 2005 and is headquartered in Burnaby, Canada.
Burnaby, British Columbia
52 Week High
52 Week Low
Yahoo FinanceMay 13
Arbutus to Present at Upcoming May 2019 Conferences
WARMINSTER, Pa., May 13, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Mark J. Murray, Arbutus’ President and CEO, will present at the following conferences in May 2019: UBS Global Healthcare Conference – New York Monday, May 20, 2019, 1:00 PM ET RBC Capital Markets Healthcare Conference – New York Tuesday, May 21, 2019, 11:00 AM ET Live webcasts of the presentations can be accessed thr...
Seeking AlphaMay 6
Arbutus Biopharma Corporation (ABUS) CEO Mark Murray on Q1 2019 Results - Earnings Call Transcript
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2019 Results Earnings Conference Call May 6, 2019 4:30 PM ET Company Participants Pam Murphy - IR Mark Murray - CEO Mike Sofia - Chief Scientific Officer Gaston Picchio - Chief Development Officer Dave Hastings - CFO Conference Call Participants Keay Nakae - Chardan Mayank Mamtani - B Riley FBR Operator Good day, ladies and gentlemen, and welcome to the Arbutus Biopharma Corporation 2019 First Quarter Financial Results and Corporate Update Conference...
Expected Aug 1, After Hours